Asymptomatic hyperuricemia following renal transplantation

Gianni Bellomo

Gianni Bellomo, Department of Nephrology, MVT Hospital, 06059 Todi(Pg), Italy

Author contributions: Bellomo G solely contributed to this paper.

Conflict-of-interest statement: The author hereby declares to hold no conflicts of interest whatsoever.

Open-Access: This is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

Correspondence to: Gianni Bellomo, MD, Department of Nephrology, MVT Hospital, Str. Del Buda, 1, 06059 Todi(Pg), Italy. assidial@tin.it
Telephone: +39-075-8880691

Received: January 25, 2015
Peer-review started: January 26, 2015
First decision: March 6, 2015
Revised: March 19, 2015
Accepted: April 16, 2015
Article in press: April 20, 2015
Published online: July 6, 2015

Abstract

Evidence is accumulating indicating a role for uric acid in the genesis and progression of kidney disease, and a few studies are beginning to show a possible beneficial effect of urate-lowering therapy. Whether this holds true for renal allograft recipients is not clear. In this short review evidence from epidemiological as well as intervention studies is summarized and discussed, with some practical considerations presented at the end.

Key words: Uric acid; Renal transplant; Urate lowering therapy; Allopurinol; Febuxostat

@ The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.

Core tip: Hyperuricemia is a common finding following renal transplantation; its clinical, as well as prognostic, significance, however, is not known. We have summarized available evidence from human epidemiological and intervention studies and concluded that, in the absence of gout, evidence in support of treatment for this condition in renal graft recipients is insufficient at present, although, when required, treatment with low-dose allopurinol or febuxostat appears to be safe.

Bellomo G. Asymptomatic hyperuricemia following renal transplantation. World J Nephrol 2015; 4(3): 324-329 Available from: URL: http://www.wjgnet.com/2220-6124/full/v4/i3/324.htm DOI: http://dx.doi.org/10.5527/wjn.v4.i3.324

INTRODUCTION

A body of evidence, accumulated mainly in the last 15 years, based on animal and human experimental studies, as well as prospective observational and a few intervention studies, reviewed elsewhere[1-5], has lent support to the hypothesis that hyperuricemia may be linked to incident renal disease and the progression of chronic kidney disease (CKD). Fewer data are available regarding the effect of uric acid (UA) and hyperuricemia on graft function and survival following renal transplantation. Aim of this short review, which does not mean to be either exhaustive or comprehensive, is to summarize available evidence gathered from observational and intervention studies on the latter topic in adult patients; we will not cover incidence and treatment of gout after renal transplantation, referring the reader interested in a more detailed discussion to the excellent review by
July 6, 2015 | Volume 4 | Issue 3 | WJN | www.wjgnet.com

Bellomo G. Hyperuricemia and renal transplantation

Stamp et al⁶¹.

Literature search was performed on the PubMed, EMBASE and Science Direct databases using the following search terms: Uric, Uric Acid, Urate, Hyperuricemia and Renal, Kidney Transplant, Transplantation, Graft, Allograft.

**EPIDEMIOLOGY OF HYPERURICEMIA FOLLOWING RENAL TRANSPLANTATION**

Hyperuricemia (serum UA greater or equal to 6.0 mg/dL in women and 7.0 mg/dL in men) is fairly common following renal transplantation. The prevalence of hyperuricemia in recipients of a renal allograft has been shown to range from 19% to 55% in patients whose immunosuppressive regimen did not include cyclosporin A (CsA) and from 30% to 84% in patients treated with CsA⁷. In the same series, incident gout was not observed in non-CsA treated patients, whereas it ranged from 2.0% to 28% following CsA therapy. More recently, Kalantar et al⁸ have measured serum UA in 12767 samples from 2961 renal graft recipients; they detected hyperuricemia in 1553 patients (52.3%, 61% men, 39% women). In another study⁹ of 302 patients with a well functioning kidney graft, at a median 7.6 years after transplantation, hyperuricemia was present in 42.1% of patients. Kim et al⁹ investigated the prevalence of hyperuricemia in 356 transplanted patients with stable renal graft function (estimated GFR > 60 mL/min per 1.73 m²). In this subgroup of patients they found raised UA levels in 55 (15.45%). Numakura et al¹⁰ found hyperuricemia to be present in 38% of patients one year after transplantation; in their cohort male gender and dialytic vintage before transplantation were predictors of post-transplant hyperuricemia. According to the various studies, risk factors for hyperuricemia following renal transplantation include decreased glomerular filtration rate (GFR), diuretic use, pre-existent history of hyperuricemia, treatment with calcineurin inhibitors, in particular CsA, use of diuretics, male gender, diabetes mellitus, hypercalcemia, and higher body weight; tacrolimus has been associated with lower odds of developing hyperuricemia, compared to CsA⁹.

**OBSERVATIONAL STUDIES EXPLORING THE ASSOCIATION BETWEEN HYPERURICEMIA AND GRAFT FUNCTION/SURVIVAL**

Table 1 summarizes the most relevant studies exploring this relationship¹⁰,¹²-¹⁵. Although most studies tend to favour an influence of UA on graft function and survival, there are notable exceptions: for instance, Meier-Kriesche et al²⁰, reviewing their data from the SYMPHONY Study, in which a cohort of 1645 was followed-up for 3 years, found that the association of baseline UA with follow-up eGFR, disappeared when adjusting for baseline eGFR. Conversely, in the study by Haririan et al²¹, after a mean 68 mo follow-up, hyperuricemia was associated with a 1.26 (95%CI: 1.03-1.53) hazard ratio (HR) of graft loss. Kim et al²⁴ recently reported their review of patients transplanted between 1990 and 2009, and they observed that hyperuricemia conferred an 1.45 (P < 0.001) HR of graft loss; however the same group, in a study enrolling transplanted patients with preserved renal function¹⁰ found hyperuricemia to be associated with decreased renal function, but not with graft survival. Choi et al²⁷ have investigated the effect of hyperuricemia on graft survival in recipients of living-donor kidney transplants, and found a nearly double incidence of graft loss in hyperuricemic patients (22.2% vs 11.4%). Hart et al²⁹, in a post-hoc analysis of patients participating in the ABCAN Trial, undergoing protocol biopsies of the graft, found an association between serum UA levels and the degree of interstitial fibrosis and tubular atrophy. In patients undergoing biopsy for acute allograft dysfunction, Weng et al⁳⁰ found hyperuricemia to be associated with a greater cumulative incidence at one year of the combined endpoint of doubling serum creatinine or graft loss (29.8% vs 14.9%, P = 0.02) compared to normouricemia. As far as cardiovascular outcomes are concerned, Dahle et al⁴⁰ after a 7.4 year follow-up of 2200 patients found a J-shaped association between serum UA levels and cardiovascular as well as all-cause mortality, with a significant increased HR in the 5th UA centile, and a similar tendency (though not reaching statistical significance) for the lowest UA quintile. Other studies have yielded conflicting results, although those with a longer follow-up, and those assessing graft survival (rather than eGFR) as an end-point, tend to favour an adverse effect of hyperuricemia. The reason for the discrepancies among studies are not completely clear; however differences in the definition of hyperuricemia, duration of follow-up, end-points evaluated, populations studied and in adjustment for confounders and comorbidities may have played a role. Recently Huang et al³³ have published a meta-analysis, including 12 studies judged to be of medium-high quality according to the Newcastle-Ottawa quality assessment scale; the results of the meta-analysis showed that hyperuricemia was a risk factor for chronic allograft nephropathy [unadjusted Odds ratio (OR) = 2.85, 95%CI: 1.84-4.38, adjusted HR = 1.65, 95%CI: 1.02-2.65] and graft loss (Unadjusted OR = 2.29, 95%CI: 1.55-3.39; adjusted HR = 2.01, 95%CI: 1.39-2.94). The authors of this meta-analysis concluded that hyperuricemia may be an independent risk factor of allograft dysfunction and may increase slightly the risk of poor outcomes.

At the moment, the evidence supporting a causative or prognostic role for serum UA in renal transplant recipients is not conclusive.
Patients undergoing biopsies for acute allograft dysfunction. Hyperuricemia was not associated with graft survival during 30 mo of follow-up in a retrospective study. Hyperuricemia associated with chronic allograft nephropathy (biopsy proven). Serum UA associated with allograft loss, but rate of eGFR decline more potent predictor.

Hypermuricemia associated with markers of endothelial dysfunction and inflammation.

Hyperuricemia associated with cardiovascular events and, inversely with eGFR after adjustment for baseline renal function.

Hyperuricemia associated with development of cyclosporine A nephropathy (biopsy proven) in some studies.

Serum UA associated to development of cyclosporine A nephropathy (biopsy proven).

Early-onset moderate-to-severe hyperuricaemia (serum UA > 8.0 mg/dL) was associated with reduced graft survival in normouricemic patients (89% vs 96% and 81% vs 93%, respectively, P = 0.02).

UA levels one month after transplantation not associated with follow-up eGFR, but rate of eGFR decline more potent predictor.

Hyperuricemia associated with markers of endothelial dysfunction and inflammation.

Hyperuricemia increased risk of cardiovascular complication; graft survival at 5 and 10 yr lower in hyperuricemic vs normouricemic patients (89% vs 96% and 81% vs 93%, respectively).

Hyperuricemia associated with chronic allograft dysfunction.

Post-hoc study of the ABCAN trial. Serum UA independently associated with increased HR of adverse events and/or absence of blinding. In a study published in 2003, Perez-Ruiz et al. \[34\] studied 279 renal allograft recipients with hyperuricemia, 89 treated with allopurinol (mean dose 185 mg/d), and 190 with the uricosuric agent benzbiodarone (mean dose 73 mg/d); the immune-suppressive regimen included azathiprine in 49.1% of patients. Both drugs were effective in reducing serum UA, with similar withdrawal rate (11% for allopurinol and 8% for benzbiodarone).

Major adverse events were rare, 3 in the allopurinol group (one case of pancytopenia, one hepatitis and one unexplained fever, all on high-dose treatment, 600 mg/d) and 2 in the benzbiodarone group (hypothyroidism). It must be remembered, however, that benzbiodarone was withdrawn from the market in many countries due to liver toxicity. More recently Numakura et al. \[11\] studied 46 patients with post-transplant hyperuricemia treated with allopurinol (100-200 mg/d) compared to placebo.

**Table 1. Studies investigating the association between serum uric acid and renal function/graft survival in patients with kidney transplantation**

| Author | Numerosity | Average follow-up | Major findings | Ref. |
|--------|------------|-------------------|----------------|-----|
| Gerhardt et al (1999) | 375 | 5 yr | Hyperuricemia (> 8.0 mg/dL in men and > 6.2 mg/dL in women, associated with reduced graft survival) | [12] |
| Armstrong et al (2005) | 90 | 2.2 yr | UA independent predictor of follow-up eGFR, but not of eGFR change over time | [13] |
| Akgul et al (2007) | 133 | 3 yr | No association found between serum UA and the development of chronic allograft nephropathy | [14] |
| Saglam et al (2008) | 34 | Not reported | Serum UA associated to development of cyclosporine A nephropathy (biopsy proven) | [15] |
| Akalin et al (2008) | 307 | 4.3 yr | Hyperuricemia 6 mo after transplantation significantly associated with new cardiovascular events and graft dysfunction | [16] |
| Bandukwala et al (2009) | 405 | 2 yr | Hyperuricemia associated with cardiovascular events, and, inversely with eGFR | [17] |
| Meyer-Kriesche et al (2009) | 1645 | 3 yr | UA levels one month after transplantation not associated with follow-up eGFR, and a poorer graft survival (P = 0.026) by multivariate analysis, whereas mild hyperuricemia was not | [18] |
| Karbowska et al (2009) | 78 | Not reported | Hyperuricemia associated with markers of endothelial dysfunction and inflammation | [19] |
| Min et al (2009) | 368 | 58 ± 23 mo | Early-onset moderate-to-severe hyperuricemia (serum UA > 8.0 mg/dL) was found to be a significant risk factor for chronic allograft nephropathy (P = 0.035) and a poorer graft survival (P = 0.026) by multivariate analysis, whereas mild hyperuricemia was not | [20] |
| Haririan et al (2010) | 212 | 68 ± 27 mo | Serum UA during the first 6 mo posttransplant, is an independent predictor of graft survival | [21] |
| Kim et al (2010) | 356 | 102.6 ± 27.2 mo | Patients with eGFR ≥ 60 mL/min per 1.73 m². Hyperuricemia associated with decreased eGFR | [22] |
| Boratyńska et al (2010) | 100 | 34 ± 12 mo | Serum UA not associated to graft survival during 30 mo of follow-up | [23] |
| Chung et al (2011) | 351 | 10 yr | Hyperuricemia increased risk of cardiovascular complication; graft survival at 5 and 10 yr lower in hyperuricemic vs normouricemic patients (89% vs 96% and 81% vs 93%, respectively, P = 0.02) | [24] |
| Kim et al (2011) | 556 | Not reported | Serum UA levels affect graft function, even after adjustment for baseline eGFR | [25] |
| Wang et al (2011) | 524 | 10 yr | Retrospective study: UA significantly lower in patients with longer graft survival | [26] |
| Park et al (2013) | 428 | 120 ± 58 mo | Serum UA associated with allograft loss, but rate of eGFR decline more potent predictor | [27] |
| Choi et al (2013) | 378 | 10 yr | Graft survival (living donor renal transplantation) 88.6% in normouricemic vs 78.8% in hyperuricemic patients | [28] |
| Dahle et al (2014) | 2200 | 7.4 yr | Highest serum UA quintile independently associated with increased HR (2.87, 95%CI: 1.55-5.32) of cardiovascular and all-cause (1.55, 95%CI: 1.09-2.25) mortality | [29] |
| Hart et al (2014) | 149 | 5 yr | Post-hoc study of the ABCAN trial. Serum UA independently associated with increased odds of composite outcome of doubling of interstitium or ESRD from Intersstitial Fibrosis/Tubular Atrophy, after adjusting for eGFR | [30] |
| Weng et al (2014) | 880 | 43.3 ± 26.3 mo | Hyperuricemia associated with poorer graft survival (60.5% vs 75.8%, P = 0.007), no difference in all-cause mortality | [31] |
| Boratyńska et al (2014) | 637 | 10 yr | Retrospective study. Hyperuricemia associated with chronic allograft dysfunction | [32] |
| Weng et al (2014) | 124 | 14.3 mo | Patients undergoing biopsies for acute allograft dysfunction. Hyperuricemia associated with a greater cumulative incidence at one year of doubling serum creatinine or graft loss (29.8% vs 14.9%, P = 0.02) compared to normouricemia | [33] |

UA: Uric acid; eGFR: Estimated glomerular filtration rate.

**INTERVENTION STUDIES**

Currently, no randomized, double-blind, controlled clinical trials of urate-lowering treatment on graft function and survival in renal allograft recipients are available. Table 2 shows the few published studies, all suffering from drawbacks such as low numerosity, lack of a placebo arm, single center, inconsistent reporting of adverse events and/or absence of blinding. In a study published in 2003, Perez-Ruiz et al. \[34\] studied 279 renal allograft recipients with hyperuricemia, 89 treated with allopurinol (mean dose 185 mg/d), and 190 with the uricosuric agent benzbiodarone (mean dose 73 mg/d); the immune-suppressive regimen included azathiprine in 49.1% of patients. Both drugs were effective in reducing serum UA, with similar withdrawal rate (11% for allopurinol and 8% for benzbiodarone). Major adverse events were rare, 3 in the allopurinol group (one case of pancytopenia, one hepatitis and one unexplained fever, all on high-dose treatment, 600 mg/d) and 2 in the benzbiodarone group (hypothyroidism). It must be remembered, however, that benzbiodarone was withdrawn from the market in many countries due to liver toxicity. More recently Numakura et al. \[11\] studied 46 patients with post-transplant hyperuricemia treated with allopurinol (100-200 mg/d) compared to placebo.
to 75 normouricemic patients, followed up to 10 years. The former group had a lower eGFR, with a tendency for graft survival at 5 and 10 years to be reduced, with borderline statistical significance. Rates of withdrawal from treatment or incidence of adverse events were not reported in this study. Osadchuck et al[35] in a retrospective case-control study, evaluated 54 hyperuricemic patients taking allopurinol because of gout, compared to 54 untreated controls matched for eGFR and time from transplant; mean baseline serum UA was 8.0 mg/dL in the allopurinol group and 6.8 mg/dL in the controls. At the end of the observation period (2 years) serum UA was reduced, and eGFR greater in the treatment group compared to controls, whereas no difference in graft survival was recorded. The dose of allopurinol used is not stated, and neither rate of withdrawal from treatment nor the incidence of adverse effects is reported. Sofue et al[34] studied 93 renal allograft recipients with stable renal function, 51 of them being hyperuricemic, 42 normouricemic. They treated 26 hyperuricemic patients with low-dose (10–20 mg/d) febuxostat, a novel xanthine-oxidase inhibitor associated with fewer adverse events than allopurinol[37]. After one year of treatment the majority of treated patients had achieved target serum UA levels and eGFR was stable. No serious adverse events were recorded and liver function tests were not altered by febuxostat. Finally, Tojimbara et al[37] assessed 22 hyperuricemic renal allograft recipients treated with low-dose febuxostat (10–20 mg/d). Despite the low dose administered, 73% of the patients achieved target serum UA levels (< 6.0 mg/dL). No serious adverse events were recorded, and only one patient withdrew from the study because of numbness in the arms. Immuno-suppressive drug levels were not affected by the co-administration of febuxostat.

**CONCLUSION**

Available evidence does not support widespread use of urate lowering therapies in asymptomatic hyperuricemic recipients of a renal allograft. At present, treatment should be limited to patients with gout, although patients with severe hyperuricemia (>8.0 mg/dL) might benefit from serum UA lowering therapy; it is not known what serum UA target should be achieved, however, a recently published[36] long-term follow-up of a randomized, controlled clinical trial of allopurinol treatment in patients with CKD, has shown that nephro-protection can be attained by lowering serum UA just below its crystallization threshold (6.8 mg/dL). The therapeutic armamentarium is currently limited to xanthine-oxidase inhibitors, as uricosuric agents, with the possible exception of losartan, are mostly not indicated, or ineffective, in patients with CKD and/or kidney transplant, uricase and its analogues are expensive, must be administered parenterally, and have important side effects; the discovery and isolation of urate transporters in the renal tubules, has led the way to the development of new hypouricemic drugs, currently under evaluation[39] but not immediately available for clinical use. The good news is that the data at hand seem to show that both allopurinol and febuxostat can be administered safely, at low doses, in renal transplant recipients, with the exception of those treated with azathioprine, the side-effects of which could be potentiated by xanthine-oxidase inhibition. In conclusion, randomized controlled trials of urate lowering therapy are badly needed in this population of patients, to establish whether preservation of renal function and prolongation of graft survival can be achieved.

**REFERENCES**

1 jalal di, chonchol m, chen w, targher g. uric acid as a target of therapy in ckd. *am j kidney dis* 2013; 61: 134-146 [pmid: 23058478 doi: 10.1053/j.ajkd.2012.07.021]

2 johnson rj, nakagawa t, jalal d, sánchez-lozada lg, kang dh, ritz e. uric acid and chronic kidney disease: which is chasing which? *nephrol dial transplant* 2013; 28: 2221-2228 [pmid: 23058478 doi: 10.1053/j.ajkd.2012.07.021]

---

**Table 2** Studies of uric-acid-lowering therapy in renal allograft recipients

| Ref. | Study population | Average follow-up | Intervention/outcome(s) | Main study findings |
|------|------------------|-------------------|--------------------------|---------------------|
| Perez-Ruiz et al[34] | 279 renal allograft recipients with hyperuricemia | 38.6 ± 18.4 mo | Allopurinol, benziodarone/serum UA levels | Both drugs effective in lowering serum UA; benziodarone safer in patients on azathioprine. Hyperuricemia associated with reduced eGFR, but graft survival similar in normo and hyperuricemic patients. |
| Numakura et al[35] | 121 renal allograft recipients with and without hyperuricemia | Up to 10 yr, mean not reported | Allopurinol/serum UA levels, eGFR, graft survival | Reduced serum UA, preservation of eGFR in allopurinol treated patients; no differences in graft survival and blood pressure. |
| Osadchuck et al[36] | 108 renal allograft recipients (54 patients treated vs 54 controls) | 2 yr | Allopurinol/serum UA levels, eGFR, graft survival | Serum UA lower and eGFR stable in patients treated with febuxostat. |
| Sofue et al[37] | 93 renal allograft recipients (42 normouricemic, 51 hyperuricemic, 26 treated, 25 not treated) | 1 yr | Febuxostat/serum UA levels, eGFR | |
| Tojimbara et al[38] | 23 renal allograft recipients with hyperuricemia | 12 ± 2 mo | Febuxostat/serum UA, eGFR | Serum UA lower after treatment with febuxostat; eGFR stable. |

UA: Uric acid; eGFR: Estimated glomerular filtration rate.
Bellomo G. Hyperuricemia and renal transplantation

Bellomo G. Uric acid and chronic kidney disease: A time to act? *World J Nephrol* 2013; 2: 17-25 [PMID: 24175261 DOI: 10.5527/v2.12.17]

Feig DI. Serum uric acid and the risk of hypertension and chronic kidney disease. *Curr Opin Rheumatol* 2014; 26: 176-185 [PMID: 24419747 DOI: 10.1097/BOR.0000000000000033]

Bose B, Badve SV, Hiremath SS, Boudville N, Brown FG, Cass A, de Zoya JR, Fassett RG, Faull R, Harris DC, Hawley CM, Kannel J, Palmer SC, Perkovic V, Pascoe EM, Rangan GK, Walker RJ, Walters G, Johnson DW. Effects of uric acid-lowering therapy on renal outcomes: a systematic review and meta-analysis. *Nephrol Dial Transplant* 2014; 29: 406-413 [PMID: 24042021 DOI: 10.1093/ndt/gft378]

Stamp LK, Chapman PT. Gout and organ transplantation. *Curr Rheumatol Rep* 2012; 14: 165-172 [PMID: 22258500]

Clive DM. Renal transplant-associated hyperuricemia and gout. *J Am Soc Nephrol* 2000; 11: 974-979 [PMID: 10779978]

Kalantar E, Khalihi N, Hossieni MS, Rosztari Z, Einollahi B. Hyperuricemia after renal transplantation. *Transplant Proc* 2011; 43: 584-585 [PMID: 21440768 DOI: 10.1016/j.transproceed.2011.01.062]

Malheiro J, Almeida M, Fonseca I, Martins LS, Pedrosa S, Dias L, Henriques AC, Cabrita A. Hyperuricemia in adult renal allograft recipients: prevalence and predictors. *Transplant Proc* 2012; 44: 2369-2372 [PMID: 23026595 DOI: 10.1016/j.transproceed.2012.07.033]

Kim KM, Kim SS, Han DJ, Yang WS, Park JS, Park SK. Uric acid contributes to glomerular filtration rate deterioration in renal transplantation. *Nephron Clin Pract* 2011; 118: c136-c142 [PMID: 21150221 DOI: 10.1159/000320616]

Wang W, Li XB, Yin H, Yang XY, Liu H, Ren L, Hu XP, Wang Y, Zhang XD. Factors affecting the long-term renal allograft survival. *Clin Med (Eng)* 2011; 124: 1181-1184 [PMID: 21542992]

Park JS, Oh IH, Lee CH, Kim GH, Kang CM. The rate of decline of glomerular filtration rate is a predictor of long-term graft outcome after kidney transplantation. *Transplant Proc* 2013; 45: 1438-1441 [PMID: 23726591 DOI: 10.1016/j.transproceed.2012.10.052]

Choi JY, Kwon OJ. The association between serum uric acid levels at 3 months after renal transplantation and the graft outcome in living donor renal transplantation. *Transplant Proc* 2013; 45: 1548-1552 [PMID: 23726617 DOI: 10.1016/j.transproceed.2012.10.062]

Dahle DO, Jenssen T, Holdaas H, Liestad T, Vårdal M, Mjøen G, Reisaeter AV, Toft I, Hartmann A. Uric acid has a J-shaped association with cardiovascular and all-cause mortality in kidney transplant recipients. *Clin Transplant* 2014; 28: 134-140 [PMID: 24372653 DOI: 10.1111/ctr.12290]

Hart A, Jackson S, Kasiske BL, Mauer MS, Najafian B, Matas AJ, Spong R, Ibrahim HN. Uric acid and allograft loss from interstitial fibrosis/tubular atrophy: post hoc analysis from the angiotensin II blockade in chronic allograft nephropathy trial. *Transplantation* 2014; 97: 1066-1071 [PMID: 24503762 DOI: 10.1097/01.TP.0000440952.29757.66]

Weng SC, Shu KH, Tang DC, Cheng CH, Chen CH, Yu TM, Chuang YW, Huang ST, Wu MJ. Uric acid is highly associated with kidney allograft survival in a time-varying analysis. *Transplant Proc* 2014; 46: 505-510 [PMID: 24656000 DOI: 10.1016/j.transproceed.2013.09.038]

Boratyńska M, Wawelenko A, Klinger M, Szyber P. Chronic allograft dysfunction in kidney transplant recipients: long-term single-center study. *Clin Transplant* 2014; 28: 2673-2677 [PMID: 25380892 DOI: 10.1111/ctr.12098]

Weng SC, Shu KH, Wu MJ, Cheng CH, Chen CH, Yu TM, Chuang YW, Huang ST, Wu MJ. Uric acid is highly associated with kidney allograft survival in a time-varying analysis. *Transplant Proc* 2014; 46; 505-510 [PMID: 24656000 DOI: 10.1016/j.transproceed.2013.09.038]

Boratyńska M, Wawelenko A, Klinger M, Szyber P. Chronic allograft dysfunction in kidney transplant recipients: long-term single-center study. *Transplant Proc* 2014; 46: 2673-2677 [PMID: 25380892 DOI: 2014.09.058]

Weng SC, Shu KH, Wu MJ, Cheng CH, Chen CH, Yu TM, Chuang YW, Huang ST, Tang DC. Hyperuricemia predicts kidney disease progression after acute allograft dysfunction. *Transplant Proc* 2014; 46: 499-504 [PMID: 24653999 DOI: 10.1016/j.transproceed.2013.09.040]

Huang Y, Li YL, Huang H, Wang L, Yuan WM, Li J. Effects of hyperuricemia on renal function of renal transplant recipients: a systematic review and meta-analysis of cohort studies. *PLoS One* 2012; 7: e39457 [PMID: 22745759 DOI: 10.1371/journal.pone.0039457]

Perez-Ruiz F, Gomez-Ullate P, Amenabar JJ, Zarraza S, Calabozo M, Herrero-Belitis AM, Nolla JM. Long-term efficacy of hyperuricaemia treatment in renal transplant patients. *Nephrol Dial Transplant* 2013; 28: 603-606 [PMID: 12584266 DOI: 10.1093/ndt/gft119.3.603]

Osadchuk L, Bashir MH, Tangirala B, Marcus RJ, Nashar K, Hussain SM, Sureshkumar K. Effect of allopurinol on slowing function in adult renal transplant recipients: evidence from the symphony study. *Clin J Am Soc Nephrol* 2009; 4: 1655-1660 [PMID: 19713295 DOI: 10.2215/CJN.02700409]
allograft functional decline in kidney transplant recipients. *Exp Clin Transplant* 2014; 12: 190-194 [PMID: 24907717]

36 **Sofue T**, Inai M, Hara T, Nishijima Y, Moriwaki K, Hayashida Y, Ueda N, Nishiyama A, Kakahi Y, Kohno M. Efficacy and safety of febuxostat in the treatment of hyperuricemia in stable kidney transplant recipients. *Drug Des Devel Ther* 2014; 8: 245-253 [PMID: 24600205 DOI: 10.2147/DDDT.S56597]

37 **Tojimbara T**, Nakajima I, Yashima J, Fuchinoue S, Teraoka S. Efficacy and safety of febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase for the treatment of hyperuricemia in kidney transplant recipients. *Transplant Proc* 2014; 46: 511-513 [PMID: 24656001]

38 **Faruque LI**, Ebeshami-Afshar A, Wiebe N, Tjosvold L, Homik J, Tonelli M. A systematic review and meta-analysis on the safety and efficacy of febuxostat versus allopurinol in chronic gout. *Semin Arthritis Rheum* 2013; 43: 367-375 [PMID: 24326033 DOI: 10.1016/j.semarthrit.2013.05.004]

39 **Goicoechea M**, García de Vinuesa S, Verdalles U, Verde E, Macias N, Santos A, Pérez de Jose A, Cedeño S, Linares T, Luño J. Allopurinol and progression of CKD and cardiovascular events: long-term follow-up of a randomized clinical trial. *Am J Kidney Dis* 2015; 65: 543-549 [PMID: 25595565 DOI: 10.1053/j.ajkd.2014.11.016]

40 **Diaz-Torné C**, Perez-Herrero N, Perez-Ruiz F. New medications in development for the treatment of hyperuricemia of gout. *Curr Opin Rheumatol* 2015; 27: 164-169 [PMID: 25663039 DOI: 10.1097/BOR.0000000000000146]

P-Reviewer: Markic D, Mu JS S-Editor: Song XX L-Editor: AE-Editor: Yan JL
